From a technical standpoint, I concur. But the author’s main argument seemed to be that AGIX management does not deserve the benefit of the doubt. On this narrow point, I’m not sure I disagree.
I agree inre management unreliability - but the technical error is not a minor one. I.e. having a working drug is important. A necessary condition - albeit not sufficient (running even part of a trial in Eastern Europe is probably a significant management error).
Market Data 
Markets 
AI
